Meds & supplements › Lazertinib
Medicine · Kinase Inhibitor
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or…
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
The following adverse reactions are discussed elsewhere in the labeling:
None.
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
sofidex [Internet]. Daloreum; c2026. Lazertinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lazertinib
sofidex. (2026, August 3). Lazertinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lazertinib
Lazertinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lazertinib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.